Drug intelligence / Profile preview

R-CAP

Development stage: Preclinical
Lead developer: StemGenn Therapeutics
Modality: Cell Therapies
Administration: Local Injection

Overview

R-CAP (Regenerative Concentrate of Active Plasma) is a biologic therapy developed by StemGenn Therapeutics. It is a platelet-rich plasma (PRP)-based therapy that utilizes a concentrated preparation of autologous platelet-derived growth factors to promote tissue regeneration. Specifically positioned for reproductive health and fertility support, R-CAP is designed to rejuvenate reproductive tissues and improve outcomes in fertility treatments. The therapy works by delivering a high concentration of bioactive proteins, including PDGF, VEGF, and TGF-beta, which stimulate cellular proliferation, angiogenesis, and tissue repair in the localized environment where it is administered.

Brand names: R-CAP
Other names: Regenerative Concentrate of Active Plasma

Beyond the preview

Go deeper on R-CAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-CAP.

Explore the full profile